| Literature DB >> 3679785 |
F Degl'Innocenti1, A Ginanneschi, S Magnolfi, L Catarzi, P Marini.
Abstract
Lisuride was investigated for therapeutic effects in 19 patients with advanced Parkinson disease, no longer satisfactorily responding to routine L-Dopa therapy. The patients were treated with oral Lisuride (0.6-2.5 mg/die) and L-Dopa. The follow-up was at least 6 months. We noted a significant improvement on the Webster Rating Scale at 1st, 3rd and 6th months. Disability and on-off phenomen were reduced. Side effects were few. Lisuride is a valuable tool in this type of patient.Entities:
Mesh：
Substances：
Year: 1987 PMID： 3679785 DOI： 10.1007/bf02335738
Source DB: PubMed Journal: Ital J Neurol Sci ISSN： 0392-0461